Fairmount Funds Management LLC
Transaction: 08/07/2026
SELL
Change
-10,370
Price
$43.85
Filing
08/11/2026
Type
SELL
Apogee Therapeutics, Inc.
APGE • Biotechnology
$135.07
— 0.00 (0.00%)
Current price
EarningsLatest report: Jun 30, 2026
HIGHER-RISK PROFILECautionConfidence: 62%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$10.19B
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.01Healthy liquidity · 26.57Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 12, 2026, 12:07 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$135.07
Change0.00%
Shares Out75.44M
Market Cap$10.19B
Enterprise Value$9.22B
52W Range34.58 - 134.88
Beta0.33
P/E-34.62
P/B8.53
P/FCF-41.77
EV/EBITDA-29.85
EV/FCF-37.79
Price$135.07
Change0.00%
Shares Out75.44M
Market Cap$10.19B
Enterprise Value$9.22B
52W Range34.58 - 134.88
Beta0.33
P/E-34.62
P/B8.53
P/FCF-41.77
EV/EBITDA-29.85
EV/FCF-37.79
Earnings Yield-2.89%
FCF Yield-2.39%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.01
Current Ratio26.57
Quick Ratio26.57
Target$130.92
Target Upside-3.07%
Target Median$135.00
Target Range89.00 - 140.00
Volume1.05M
Avg Volume2.06M
EPS Surprise0.01
Investment DNA
How strong this company looks for long-term investors
42
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
61/100
Why this score▼
Manageable debt level · 0.01Healthy liquidity · 26.57Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 14 analyst votes · 2026-09-05
57/100
Neutral
Bullish
2
Hold
12
Bearish
0
Price Target
2026-08-12
Low
$81.00
Mean
$125.52
Median
$135.00
High
$140.00
Insider Transactions
Recent executive and insider activity
Fairmount Funds Management LLC
Transaction: 08/07/2026
BUY
Change
+31,838
Price
$17.00
Filing
08/11/2026
Type
BUY
Dambkowski Carl
Transaction: 08/05/2026
SELL
Change
-4,125
Price
$22.86
Filing
08/07/2026
Type
SELL
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Fairmount Funds Management LLC | SELL | -10,370 | $43.85 | 08/07/2026 | 08/11/2026 |
| Fairmount Funds Management LLC | BUY | +31,838 | $17.00 | 08/07/2026 | 08/11/2026 |
| Dambkowski Carl | SELL | -4,125 | $22.86 | 08/05/2026 | 08/07/2026 |
| Dambkowski Carl | SELL | -5,500 | $134.17 | 08/05/2026 | 08/07/2026 |
| Henderson Jane | SELL | -15,000 | Not reported | 07/24/2026 | 07/24/2026 |
| Dambkowski Carl | SELL | -8,000 | Not reported | 07/14/2026 | 07/16/2026 |
| HENDERSON MICHAEL THOMAS | SELL | -75,046 | Not reported | 07/10/2026 | 07/10/2026 |
| HENDERSON MICHAEL THOMAS | SELL | -20,000 | $133.63 | 07/08/2026 | 07/10/2026 |
| Dambkowski Carl | SELL | -4,125 | $22.86 | 07/01/2026 | 07/02/2026 |
| Dambkowski Carl | SELL | -5,500 | $132.74 | 07/01/2026 | 07/02/2026 |
| HENDERSON MICHAEL THOMAS | SELL | -80,000 | $132.54 | 06/22/2026 | 06/24/2026 |
| Dambkowski Carl | SELL | -26,400 | $132.60 | 06/22/2026 | 06/24/2026 |
| HENDERSON MICHAEL THOMAS | SELL | -614 | $86.89 | 06/10/2026 | 06/12/2026 |
| Bollinger Lisa | BUY | +7,657 | $85.00 | 06/09/2026 | 06/11/2026 |
| Fox Jennifer A. | BUY | +7,657 | $85.00 | 06/09/2026 | 06/11/2026 |
| JONES WILLIAM A JR | BUY | +7,657 | $85.00 | 06/09/2026 | 06/11/2026 |
| McKenna Mark C. | BUY | +7,657 | $85.00 | 06/09/2026 | 06/11/2026 |
| Shah Nimish P | BUY | +7,657 | $85.00 | 06/09/2026 | 06/11/2026 |
| Fairmount Funds Management LLC | BUY | +7,657 | $85.00 | 06/09/2026 | 06/11/2026 |
| Dambkowski Carl | SELL | -4,125 | $22.86 | 06/03/2026 | 06/05/2026 |